Cargando…

Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy

Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA's benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Andrew, Elbakry, Amr A., Trump, Tyler, Prisneac, Ion, Smolkin, Matthew, Zekan, David, Salkini, Mohamad W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937751/
https://www.ncbi.nlm.nih.gov/pubmed/36818742
http://dx.doi.org/10.1155/2023/7301284
_version_ 1784890491801698304
author Williams, Andrew
Elbakry, Amr A.
Trump, Tyler
Prisneac, Ion
Smolkin, Matthew
Zekan, David
Salkini, Mohamad W.
author_facet Williams, Andrew
Elbakry, Amr A.
Trump, Tyler
Prisneac, Ion
Smolkin, Matthew
Zekan, David
Salkini, Mohamad W.
author_sort Williams, Andrew
collection PubMed
description Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA's benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-specific membrane antigen positron emission tomography (PSMA PET) can help localize the location of recurrences for better excision and management. Here, we present a 55-year-old with prostate cancer, with initially undetectable postprostatectomy PSA levels, who later presented with a PSA of 3.47 ng/mL. PSMA PET showed isolated uptake in an abdominal wall mass. Pelvic lymphadenectomy and abdominal wall mass excision were performed, confirming a single metastasis in an abdominal wall lymph node. Metastasectomy led to a dramatic drop in PSA to 0.10 ng/mL both postoperatively and on long-term follow-up. Our case illustrates the potential benefit of metastasis-directed therapy in delayed oligometastasis following definitive management of prostate cancer.
format Online
Article
Text
id pubmed-9937751
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-99377512023-02-18 Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy Williams, Andrew Elbakry, Amr A. Trump, Tyler Prisneac, Ion Smolkin, Matthew Zekan, David Salkini, Mohamad W. Case Rep Urol Case Report Prostate cancer patients routinely undergo surveillance for recurrence using prostate-specific antigen (PSA). While PSA's benefit in screening is controversial, its use for detecting recurrence in patients with history of prostate cancer is pivotal. Rising PSAs with the newly advanced prostate-specific membrane antigen positron emission tomography (PSMA PET) can help localize the location of recurrences for better excision and management. Here, we present a 55-year-old with prostate cancer, with initially undetectable postprostatectomy PSA levels, who later presented with a PSA of 3.47 ng/mL. PSMA PET showed isolated uptake in an abdominal wall mass. Pelvic lymphadenectomy and abdominal wall mass excision were performed, confirming a single metastasis in an abdominal wall lymph node. Metastasectomy led to a dramatic drop in PSA to 0.10 ng/mL both postoperatively and on long-term follow-up. Our case illustrates the potential benefit of metastasis-directed therapy in delayed oligometastasis following definitive management of prostate cancer. Hindawi 2023-02-10 /pmc/articles/PMC9937751/ /pubmed/36818742 http://dx.doi.org/10.1155/2023/7301284 Text en Copyright © 2023 Andrew Williams et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Williams, Andrew
Elbakry, Amr A.
Trump, Tyler
Prisneac, Ion
Smolkin, Matthew
Zekan, David
Salkini, Mohamad W.
Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
title Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
title_full Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
title_fullStr Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
title_full_unstemmed Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
title_short Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy
title_sort solitary abdominal wall lymph node recurrence in prostate cancer patient with dramatic prostate-specific antigen decrease following metastasectomy
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9937751/
https://www.ncbi.nlm.nih.gov/pubmed/36818742
http://dx.doi.org/10.1155/2023/7301284
work_keys_str_mv AT williamsandrew solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy
AT elbakryamra solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy
AT trumptyler solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy
AT prisneacion solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy
AT smolkinmatthew solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy
AT zekandavid solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy
AT salkinimohamadw solitaryabdominalwalllymphnoderecurrenceinprostatecancerpatientwithdramaticprostatespecificantigendecreasefollowingmetastasectomy